TriSalus Life Sciences, Inc. (ticker: TLSI) is an NASDAQ-listed clinical biotech company. DredgeCap's structured extraction of TLSI's SEC filings surfaces 6 active risk signals, including 3 late-filing signals, 2 auditor-change signals, and 1 delisting/deregistration signal. TLSI reported $8.90M in revenue and $1.54M for the period ending 2026-03-31, with operating cash flow of -$6.48M. Cash and equivalents stood at $56.55M (up 335% year-over-year). Total assets of $70.98M exceed total liabilities of $58.17M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
TLSI Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for TriSalus Life Sciences, Inc. (TLSI) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.